久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial americanpharmaceuticalreview
    November 10, 2018
    OncoSec announced the first patient has been treated in KEYNOTE-890, a Phase 2 clinical trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene telseplasmid, plus electropora
PharmaSources Customer Service